3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
19
Breast Neoplasms
18
Fallopian Tube Neoplasms
13
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neuroendocrine Tumors
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Interventions
ruxolitinib
9
fludarabine
9
Whole-Body Irradiation
9
fludarabine phosphate
8
Cyclophosphamide
8
Specimen Handling
7
Cytarabine
7
Mycophenolic Acid
6
Tacrolimus
5
Peripheral Blood Stem Cell Transplantation
5
Injections
5
Busulfan
5
Biopsy
5
Azacitidine
5
Stem Cell Transplantation
4
Sirolimus
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
CPX-351
4
venetoclax
3
luspatercept
3
decitabine and cedazuridine drug combination
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
selinexor
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
olaparib
×
90 days
×
Clear all
No trials found.